(Q40183798)

18 September 2017

1 reference

title

Calcium channel blockers in emergency medicine (English)

1 reference

18 September 2017

Young GP

1

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 September 1984

1 reference

Annals of Emergency Medicine

18 September 2017

published in

1 reference

18 September 2017

volume

13

1 reference

18 September 2017

issue

9 Pt 1

1 reference

18 September 2017

page(s)

712-722

1 reference

Mechanism of Action of Calcium-Channel-Blocking Agents

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Specific Pharmacology of Calcium in Myocardium, Cardiac Pacemakers, and Vascular Smooth Muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Role of the slow current in cardiac electrophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part I: Basic and Clinical Electrophysiologic Effects

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

The effects of calcium channel blocking agents on cardiovascular function

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment by equilibrium-gated radionuclide ventriculography

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Influence of nifedipine left ventricular systolic and diastolic function. Relationships to manifestations of ischemia and congestive failure

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Divergent effects of diltiazem in patients with exertional angina

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Calcium-channel blockers and beta blockers: Advantages and disadvantages of combination therapy in chronic stable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Effects of verapamil on supraventricular tachycardia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Effect of verapamil in infants with paroxysmal supraventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil in the treatment of paroxysmal supraventricular tachycardia in infants and children

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Safety and efficacy of short- and long-term verapamil therapy in children with tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

The clinical use of intravenous verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Physiological disposition of verapamil in man

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Clinical relevance of verapamil plasma levels in stable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Prolongation of verapamil elimination kinetics during chronic oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil versus placebo in relieving stable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

The influence of verapamil on serum digoxin concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Digoxin plasma concentrations and nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil and digoxin: their respective effects on atrial fibrillation and their interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Comparative effects of three calcium antagonists, diltiazem, verapamil and nifedipine, on the sinoatrial and atrioventricular nodes. Experimental and clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Clinical use of a calcium antagonistic agent (nifedipine) in acute pulmonary edema

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Acute hemodynamic effects of nifedipine in patients with ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Nifedipine, a new antihypertensive with rapid action

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Intracardiac electrophysiologic study of intravenous diltiazem and combined diltiazem-digoxin in patients

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Electrophysiologic effects of diltiazem, a calcium antagonist, in patients with impaired sinus or atrioventricular node function

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Hemodynamics and coronary flow following diltiazem administration in anesthetized dogs and in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

The pharmacokinetics of diltiazem in healthy American men

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Short- and long-term efficacy of high-dose oral diltiazem for angina due to coronary artery disease: a placebo-controlled, randomized, double-blind crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Beneficial effect of intravenous diltiazem in the acute management of paroxysmal supraventricular tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Electrophysiologic effects of diltiazem hydrochloride on supraventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Effect of verapamil studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Comparison of the electrophysiologic effects of intravenous and oral verapamil in patients with paroxysmal supraventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Slow channel calcium antagonists in the treatment of supraventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Effects of oral diltiazem in paroxysmal supraventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Effects of verapamil on electrophysiological properties of anomalous atrioventricular connexion in Wolff-Parkinson-White syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil in atrial fibrillation: The expected, the unexpected, and the unknown

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil in atrial fibrillation and atrial flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Calcium and calciferol antagonise effect of verapamil in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Clinical manifestations and pathophysiology of myocardial ischemia with special reference to coronary artery spasm and the role of slow channel calcium blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Long-term follow-up of verapamil and nitrate treatment for coronary artery spasm.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil versus propranolol for angina at rest

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Prevention of nifedipine of abnormal coronary vasoconstriction in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Nifedipine therapy for coronary-artery spasm. Experience in 127 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

A controlled trial of verapamil for Prinzmetal's variant angina

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Efficacy of nifedipine therapy in patients with refractory angina pectoris: Significance of the presence of coronary vasospasm

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Nifedipine in unstable angina: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Efficacy of nifedipine in rest angina refractory to propranolol and nitrates in patients with obstructive coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Hemodynamic effects of a single oral dose of nifedipine following acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil in Treatment of Chronic Stable Angina

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Interim report of multicenter double-blind, placebo-controlled studies of nifedipine in chronic stable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil for unstable angina at rest: a short-term randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Inpatient treatment of unstable angina: clinical perspective and sequential management

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Adjunctive nifedipine therapy in high-risk, medically refractory, unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Rationale for the choice of calcium antagonists in chronic stable angina. An objective double-blind placebo-controlled comparison of nifedipine and verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Possible coronary spasm rebound to abrupt nifedipine withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Production of ischaemic cardiac pain by nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiving propranolol: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Nifedipine and propranolol: a beneficial drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Hemodynamic and electrophysiologic effects of verapamil and nifedipine in patients on propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Nifedipine in hypertensive emergencies.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Treatment of hypertension with nifedipine, a calcium antagonistic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Short- and long-term efficacy of a calcium-antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Does verapamil have a clinically significant antihypertensive effect?

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Effects of diltiazem on cardiovascular responses during exercise in systemic hypertension and comparison with propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Afterload reduction with nifedipine in aortic insufficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Haemodynamic effects of nifedipine in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Hemodynamic effects of nifedipine in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Acute hemodynamic effects of combined therapy with digoxin and nifedipine in patients with chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Acute hemodynamic effect of oral nifedipine in severe chronic congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Effect of flunarizine on canine cerebral cortical blood flow and vascular resistance post cardiac arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Laboratory and initial clinical studies of nifedipine, a calcium antagonist for improved myocardial preservation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Myocardial protection through cold cardioplegia using diltiazem, a calcium channel blocker

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Early amelioration of neurologic deficit by lidoflazine after fifteen minutes of cardiopulmonary arrest in dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in Patients with Subarachnoid Hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Asystole after verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil in cardiac arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Effect of verapamil on normal sinoatrial node function and on sick sinus syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Nifedipine therapy in angina pectoris: evaluation of safety and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Unpredictable response to nifedipine in severe cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Adverse interaction between nifedipine and beta-blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Pulmonary oedema precipitated by nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Nifedipine and beta-blocker drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Nifedipine and beta-blockade as a cause of cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Cerebral ischaemia after nifedipine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Multiclinic controlled trial of diltiazem for Prinzmetal's angina

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Conduction abnormalities due to diltiazem.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Reversal of the cardiovascular effects of verapamil by calcium and sodium: differences between electrophysiologic and hemodynamic responses

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Calcium for myocardial depression from verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Verapamil Acute Self-Poisoning

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Serious verapamil poisoning: treatment with intravenous calcium gluconate

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Nifedipine in unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Acute intoxication with verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

Diltiazem and akathisia.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2884%2980734-9

7 January 2021

10.1016/S0196-0644(84)80734-9

Identifiers

DOI

1 reference

18 September 2017

1 reference